Aura Biosciences highlighted bel-sar as a potential vision-preserving frontline therapy for early choroidal melanoma, a segment estimated at about 11,000 cases yearly.
Phase 3 CoMpass registration trial is fully enrolled with 108 participants, backed by an FDA Special Protocol Assessment; primary endpoint is time to tumor progression.
Topline data from the 15-month primary efficacy analysis are projected for 2H 2027; trial includes a sham-control arm with global sites.
Phase 2 results and development timeline
Phase 2 data showed 80% tumor control at 12 months in phase 3-eligible patients on a 3-cycle regimen; 9 of 10 preserved visual acuity.
Cash runway under the current operating plan is expected into 1H 2029; bel-sar development also targets choroidal metastases and ocular surface cancers.
AURA•
